Constructing a Novel Amino Acid Metabolism Signature: A New Perspective on Pheochromocytoma Diagnosis, Immune Landscape, and Immunotherapy
Open Access
- 25 March 2024
- journal article
- research article
- Published by Springer Nature in Biochemical Genetics
- Vol. 63 (1) , 850-874
Abstract
Pheochromocytoma/paraganglioma (PGPG) is a rare neuroendocrine tumor. Amino acid metabolism is crucial for energy production, redox balance, and metabolic pathways in tumor cell proliferation. This study aimed to build a risk model using amino acid metabolism-related genes, enhancing PGPG diagnosis and treatment decisions. We analyzed RNA-sequencing data from the PCPG cohort in the GEO dataset as our training set and validated our findings using the TCGA dataset and an additional clinical cohort. WGCNA and LASSO were utilized to identify hub genes and develop risk prediction models. The single-sample gene set enrichment analysis, MCPCOUNTER, and ESTIMATE algorithm calculated the relationship between amino acid metabolism and immune cell infiltration in PCPG. The TIDE algorithm predicted the immunotherapy efficacy for PCPG patients. The analysis identified 292 genes with differential expression, which are involved in amino acid metabolism and immune pathways. Six genes (DDC, SYT11, GCLM, PSMB7, TYRO3, AGMAT) were identified as crucial for the risk prediction model. Patients with a high-risk profile demonstrated reduced immune infiltration but potentially higher benefits from immunotherapy. Notably, DDC and SYT11 showed strong diagnostic and prognostic potential. Validation through quantitative Real-Time Polymerase Chain Reaction and immunohistochemistry confirmed their differential expression, underscoring their significance in PCPG diagnosis and in predicting immunotherapy response. This study’s integration of amino acid metabolism-related genes into a risk prediction model offers critical clinical insights for PCPG risk stratification, potential immunotherapy responses, drug development, and treatment planning, marking a significant step forward in the management of this complex condition.Keywords
Funding Information
- Young Elite Scientists Sponsorship Program by Henan Association for Science and Technology (NO.2022HYTP043)
- Key Project of Henan Medical Science & Technology (2020zd-02)
- Investigation Project of Social Science Circles Federation of Henan Province (No.SL;-2023-1363)
- the Joint Project of Henan Medical Science & Technology (NO.LHGI20230060)
This publication has 56 references indexed in Scilit:
- Impad1 and Syt11 work in an epistatic pathway that regulates EMT-mediated vesicular trafficking to drive lung cancer invasion and metastasisCell Reports, 2022
- Conserved pan-cancer microenvironment subtypes predict response to immunotherapyCancer Cell, 2021
- Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2020
- Emerging Roles for Branched-Chain Amino Acid Metabolism in CancerCancer Cell, 2020
- Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and IrinotecanClinical Colorectal Cancer, 2019
- Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine TumoursEndocrine Pathology, 2017
- Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progressionCellular and Molecular Life Sciences, 2015
- Accessories to the Crime: Functions of Cells Recruited to the Tumor MicroenvironmentCancer Cell, 2012
- Butein suppresses c-Myc-dependent transcription and Akt-dependent phosphorylation of hTERT in human leukemia cellsCancer Letters, 2009
- Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazineCancer, 2008